Literature DB >> 12958656

[XBP-1 enhances the transcriptional activity of estrogen receptor alpha].

Li-Hua Ding1, Qi-Nong Ye, Jian-Hua Zhu, Jing-Hua Yan, Hong-Jun Zhong, Zong-Hua Wang, Cui-Fen Huang.   

Abstract

The estrogen receptor (ERalpha) is a member of a large superfamily of nuclear receptors that regulates the transcription of estrogen-responsive genes. Several recent studies have demonstrated that human X-box binding protein 1 (XBP-1) mRNA expression is associated with ERalpha status in breast tumors. More recently, two forms of XBP-1 were identified due to their unique splicing. The two splicing variants of XBP-1 were designated XBP-1S and XBP-1U, respectively. In this study, the coding sequences of XBP-1S and XBP-1U were cloned respectively into the expression vector pcDNA3 harboring FLAG epitope, generating the recombinant plasmids pcDNA3-FLAG-XBP-1S and pcDNA3-FLAG-XBP-1U. Western blot analysis showed that both XBP-1S and XBP-1U were expressed in mammalian cells. To determine the effects of XBP-1S and XBP-1U on the transcriptional activity of ERalpha, MDA-MB-231 breast cancer cells were cotransfected with the expression vectors for ERalpha and either pcDNA3-FLAG-XBP-1S or pcDNA3-FLAG-XBP-1U. The results indicated that XBP-1S and XBP-1U enhanced ERalpha-mediated transcriptional activities in a hormone-independent manner. GST pull-down assay showed that both XBP-1S and XBP-1U interacted with ERalpha. These data suggest that XBP-1S and XBP-1U may play an important role in breast cancer growth and progression through ERalpha signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958656

Source DB:  PubMed          Journal:  Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)        ISSN: 0582-9879


  2 in total

Review 1.  Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response.

Authors:  Rebecca B Riggins; Mary M Mazzotta; Omar Z Maniya; Robert Clarke
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

Review 2.  Endocrine resistance in breast cancer--An overview and update.

Authors:  Robert Clarke; John J Tyson; J Michael Dixon
Journal:  Mol Cell Endocrinol       Date:  2015-10-09       Impact factor: 4.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.